RANDOMIZED TRIAL OF RECOMBINANT GM-CSF FOR PATIENTS W/ ACUTE LUNG INJURY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 被诊断患有危及生命的疾病的患者，被称为急性肺损伤或急性呼吸窘迫综合征(ARDS)，已经安装了帮助呼吸的机械呼吸机，将被考虑参加这项研究。这项研究的目的是找出一种名为沙格拉司汀的药物是否可以帮助急性肺损伤或ARDS患者。沙格拉莫替丁也被称为GM-CSF。沙格拉司汀已被FDA批准用于治疗某些类型的癌症或癌症治疗引起的并发症，一些动物研究表明，它也可能对ARDS患者有所帮助。沙格拉莫替丁是一种生物化合物，它已经存在于人体内，特别是在肺部。这对保持肺部健康很重要。沙格拉莫替丁可以帮助肺内受损细胞更快地愈合，还可以帮助肺部对抗可能导致感染的细菌。它还可以防止或减少肺部的疤痕形成。这项研究可能会帮助我们在未来为ARDS患者开发更好的治疗方法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients diagnosed with a life-threatening illness that has injured your lungs, called acute lung injury or Acute Respiratory Distress Syndrome (ARDS) who have been put on a mechanical ventilator, to help breathe, will be considered for enrollment in the study. The purpose of this study is to find out whether a drug called Sargramostim can help patients with acute lung injury or ARDS. Sargramostim is also known as GM-CSF. Sargramostim has been approved by the FDA to treat complications arising from some types of cancer or cancer treatment, and some studies using animals suggest that it may also help ARDS patients. Sargramostim is a biological compound that is already in the body, especially in the lungs. It is important for keeping lungs healthy. Sargramostim may help injured cells inside the lung heal faster, and it may help lungs fight against bacteria that can cause infections. It may also prevent or decrease scarring in the lungs. This study may help us develop better treatment for patients with ARDS in the future.'